Friday, 16 October 2026European Markets

POLIGHT Stock Over 12% Down So Far Today

Loading stream...

(VIANEWS) - Shares of POLIGHT (Oslo Børs Benchmark Index_GI: PLT.OL) slid by a staggering 12.08% to kr13.10 at 14:37 EST on Wednesday, after three sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI is rising 0.33% to kr1,213.80, following the last session's upward trend. This seems, at the moment, a somewhat positive trend trading session today.

POLIGHT's last close was kr16.00, 52.94% below its 52-week high of kr34.00.

About POLIGHT

poLight ASA develops optical lens for consumer devices and industrial applications. Its lens replicates the lens of the human eye enabling the implementation of autofocus functions for various applications. Its product portfolio includes Tunable Optical Lens (TLens) products; Tlens Silver and Tlens Silver Premium; and ASIC drivers that control the supply of variable voltage to Tlens products and makes them to change focus. The company offers its products for use in front and back camera phones; wearables, including AR/VR devices; tablet PCs; HD video cameras; drones; handheld devices; and barcode readers, as well for medical equipment. It has operations in Europe, Asia, and the United States. poLight ASA was founded in 2005 and is headquartered in Horten, Norway.

Earnings Per Share

As for profitability, POLIGHT has a trailing twelve months EPS of kr-1.1.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -31.52%.

Volume

Today's last reported volume for POLIGHT is 262095 which is 193.49% above its average volume of 89301.

More news about POLIGHT (PLT.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com